LIR Life Sciences Initiates Ex Vivo Study on Protamine's Efficacy in Transdermal Delivery

LIR Life Sciences Corp. has announced the start of its controlled ex vivo study to explore whether protamine improves the skin penetration of macromolecular therapeutics. The research uses porcine skin, resembling human skin, to assess the transdermal movement of larger molecules traditionally administered via injection. The study involves the application of fluorescently labeled molecules with and without protamine. Results will be analyzed to identify potential enhancements in skin permeability, which could lead to needle-free solutions for delivering complex therapies.

Conducted alongside an independent lab, this experiment focuses on technical feasibility, examining how protamine may support the transdermal delivery of complex molecules. Edward Mills, CEO of LIR, emphasized that successful results may pave the way for developing new therapeutic targets and formulations, ultimately expanding treatment options beyond current injection-dependent therapies.